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This paper is submitted in satisfaction of the course requirement for Professor Hutt’s  
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ABSTRACT 
 
  The Food and Drug Administration (FDA) currently categorizes nonemergency oral 
contraceptives as prescription-only instead of nonprescription, or over-the-counter, drugs.  The 
time has come for the FDA to reconsider this decision and allow oral contraceptives to be 
prescribed on an over-the-counter basis.  The high safety level of oral contraceptives, numerous 
studies indicating that greater misuse of oral contraceptives will not occur if they are available 
over-the-counter, and an assessment of collateral factors relating to oral contraceptive use 
support this conclusion.  Additionally, should the FDA create a new class of behind-the-counter 
drugs, considerations of access, cost, privacy, and pharmacist interference with women’s right to 
make their own birth control determinations indicate that it would still be more appropriate to 












   3 
How  did  we  get  ourselves  into  such  a  mess?  In  my  view,  what  has  brought  out  the  harsh, 
controlling streak in so many people is that emergency contraception has to do with sex, and that 
the resultant commingling of sex with politics and morality is highly corrosive.  Why does sex get 
people’s backs up?  Like all powerful forces—terrorism, hurricanes, pandemics—the power of 
sex can seem appalling, terrifying, something that must therefore be controlled at all costs. 
- Frank Davidoff, Sex, Politics, and Morality at the FDA:  Reflections on the Plan B Decision
1  
 
I.  INTRODUCTION 
Historically, the issue of access to contraceptives in the United States has been a highly 
contentious one.  The enactment of the 1873 Comstock Act, which criminalized so much as 
importing, mailing, or transporting in interstate commerce any form of literature about birth 
control or any device designed for preventing conception or causing abortion,
2 established the 
tone for future battles over freedom of choice and morality in relation to contraception.  Ever 
since the introduction of oral contraceptives (OCs) in the early 1960s, the “Pill” has only been 
available to women in the United States who have obtained a prescription for it from a 
physician.
3  In spite of scientific advancements over the past few decades which have greatly 
enhanced the safety of OCs, the considerable positive side effects of using OCs, and studies from 
other countries which indicate that on the whole over-the-counter (OTC) prescription of OCs is 
generally safe and efficacious for women, the Food and Drug Administration (FDA) has not yet 
elected to move OCs from the prescription-only category of drugs to the nonprescription OTC 
drug category.  In this paper, I will make the case that the FDA should reclassify OCs from 
prescription drugs to OTC drugs.  I will then argue that even if the FDA creates a new class of 
behind-the-counter (BTC) drugs, a step which has been debated over the past decade, OCs 
                                                 
1  Frank Davidoff, Sex, Politics, and Morality at the FDA:  Reflections on the Plan B Decision, 
36 HASTINGS CTR. REP. 20, 25 (2006). 
2  See generally James Trussell et. al., Should Oral Contraceptives Be Available Without 
Prescription?, 83 AM. J. PUB. HEALTH 1094 (1993).  
3  Id.   4 
should still be identified as OTC drugs rather than BTC drugs. 
 
II.  A BRIEF HISTORY OF THE DISTINCTION BETWEEN PRESCRIPTION AND 
OTC DRUGS  
  The 1938 Federal Food, Drug, and Cosmetic Act (FD&C Act), which provides the 
backbone of modern food and drug law, does not set forth any guidelines for distinguishing 
between prescription and OTC drugs.
4  Within half a year of the 1938 Act’s passage, however, 
the FDA promulgated regulations outlining the distinction between these two drug categories.
5  
Under these regulations and the FD&C Act as it then stood, any drug for which adequate usage 
directions could be provided to the public through the drug’s labeling was to be sold OTC, and 
all other drugs were to be prescription only.
6  In 1944, the FDA amended the 1938 regulations to 
clarify the distinction between prescription/nonprescription drug status.
7  In a show of support 
for the FDA’s regulations, Congress echoed the FDA’s chosen method of distinguishing between 
prescription and OTC drugs in the 1951 Durham-Humphrey Amendments to the FD&C Act.
8   
The Durham-Humphrey Amendments added section 501(b)(1) to the FD&C Act.
 9  
Section 501(b)(1) provides that prescription drugs are ones which meet one or more of the 
following criteria: (A) habit-forming drugs listed in section 502(d) of the Act and their 
derivatives; (B) drugs unsafe for use except under the supervision of a licensed practitioner; and 
                                                 
4  Alan H. Kaplan, Over-the-Counter and Prescription Drugs:  The Legal Distinction Under 
Federal Law, 37 FOOD DRUG COSM. L.J. 441 (1982). 
5  Id. 
6  Peter Barton Hutt, A Legal Framework for Future Decisions on Transferring Drugs form 
Prescription to Nonprescription Status, 37 FOOD DRUG COSM. L.J. 427, 431 (1982). 
7  Id. at 431-32. 
8  Id. at 428. 
9  Id. at 432.   5 
(C) drugs limited to prescription sale under a New Drug Application (NDA).
10  Because the first 
and third categories are clear-cut, the uncertainty as to whether a drug should be classified as 
prescription or OTC arises only as to the second category.
11  In assessing if a particular drug is 
unsafe for use except under the supervision of a practitioner, the FDA considers three primary 
factors: (1) its toxicity; (2) its potential for inducing a harmful effect; and (3) its method of use 
and/or any other measures necessary for is use.
12   
In a nutshell, the first of these factors, toxicity, refers to drugs that have a low safety 
margin and, as a result, need to have their concentration adjusted by a professional in order to 
prove effective yet safe for patient use.
13  Standing alone, however, the possibility that toxicity 
would result from drug misuse is not enough to place a drug in mandatory prescription-only 
status.
14  In many instances, labeling of OTC drugs to provide clear and sufficiently detailed 
information for use is fully capable of providing an effective alternative to requiring all drugs 
with any toxicity potential to be prescription-only.
15   
The second factor, the drug’s potential for causing harmful effects, involves an 
assessment of the wide-ranging ways in which the drug might cause harm in addition to mere 
toxicity alone.
16  The drug’s potential for abuse, its interaction with food and other products, the 
likelihood of widespread use of the drug leading to patient tolerance or pathogenic resistance, the 
chance of tampering with OTC products, and the possibility of some OTC drug ingredients being 
used in counterfeit drug sales of drugs on the streets are just some of the potential ways in which 
                                                 
10  Id. at 433. 
11  Id. 
12  Id. 
13  Id. 
14  Id. at 434. 
15  Id. 
16  Id. at 435.   6 
a drug available OTC might cause harm.
17  As with toxicity, adequate consumer labeling can 
address some of these concerns, namely those relating to potential for abuse and interaction.
18   
The third factor, method of use and additional measures necessary for use, is the most 
far-reaching of these considerations.
19  The legislative history of the 1951 Amendments indicates 
that the prescription/nonprescription status assessment was meant to cover any threat to public 
health in general.
20  Thus, this factor reaches all aspects of the circumstances under which a 
particular drug is used, including issues of social policy.
21  The possibility of layperson self-
diagnosis of conditions, the need for doctors to supervise the administration of a drug and 
subsequent patient progress, the realities of the medical and pharmaceutical professions, 
overarching social policy goals, and the desire of drug companies to reap enhanced profits 
through widespread OTC drug availability are all relevant considerations in this assessment 
process.
22  Additionally and perhaps most importantly, adequate labeling once again plays a 
major role in the analysis.
23  Indeed, of all of the considerations relating to both this factor and 
the others, the most important by far are the drug’s margin of safety, its potential to be abused if 
made available OTC, and the availability of sufficient labeling.
24 
  The majority of the remainder of this paper will focus on applying these three factors to 
the prescription/OTC status determination for nonemergency OCs.  First, the safety of OTC use 
of OCs will be addressed.  Second, the high level of efficacy and relatively low potential for 
harmful effects resulting from OTC sales of OCs will be set forth.  I will then argue that the 
                                                 
17  Id. at 435-36. 
18  Id. at 435. 
19  Id. at 436. 
20  Id. at 433. 
21  Id. 
22  Id. at 436-39. 
23  Id. at 438. 
24  Id. at 440.   7 
method of use and other collateral measures pertaining to OTC use of nonemergency oral 
contraceptives do not provide sufficient reason to keep OCs prescription-only.  Because some of 
the same considerations are involved in each of these areas, some issues may be appropriate for 
consideration in one or more of these sections and either be discussed from slightly different 
perspectives in each category or only covered in one section.  My brief final argument will be 
that should the FDA create a new class of behind-the-counter (BTC) drugs, OCs should still be 
identified as OTC drugs rather than BTC drugs. 
 
III.  FACTOR ONE IN PRECRIPTION/OTC ANALYSIS:  TOXICITY AND MARGIN 
OF SAFETY  
  OCs are currently some of the most well-studied drugs in existence, and research 
indicates that while as with most drugs OC use entails some risks, it can also lead to many 
significant benefits.
25  Indeed, research has shown that in addition to safeguarding women from 
unintended pregnancies and the resultant health risks, OCs protect against a wide variety of 
conditions including pelvic inflammatory disease, ectopic pregnancy, iron deficiency anemia, 
primary dysmenorrhea, and benign breast disease.
26  OC use also reduces the incidence of 
ovarian cancer in users by a staggering 30-50% and provides protection against endometrial 
cancer proportional to the duration of use and for up to 15 years after discontinuation.
27  One of 
the most recent studies has even indicated that women who use oral contraceptives at some point 
in their lives face a significantly lower risk of death resulting from any cause, including heart 
                                                 
25  Trussell, supra note 2, at 1095. 
26  Id. 
27  Helen Rees, Acquiring the Pill:  Safety Issues, 2 REPROD. HEALTH MATTERS 41 (1994).   8 
disease and cancers, compared with women who have never taken them.
28  It seems plausible 
that this latest finding may turn out to be due at least some extent to the fact that many women 
who do not use oral contraceptives may choose not to do so because they already engage in other 
health-threatening behaviors such as smoking which render OC use riskier for them.  
Nonetheless, on the whole, the benefits of OC use are striking. 
  Safety risks relating to OC use include some possibility of increasing a woman’s chance 
of getting breast cancer, although most studies show no overall impact of OC use on this risk, 
and a possible link to increased rates of cervical neoplasia.
29  As for cardiovascular disease, it 
appears to be unrelated to low-dose OC use, at least when users are subject to screening.
30  Even 
if a causal relationship does exist between OC use and these conditions, however, considering 
the many positive effects of OC use and thinking in terms of overall safety, it may actually be 
healthier for women to use OCs for at least some time than to abstain from utilizing them 
altogether.    
  A limited number of conditions for which OC use is contraindicated currently exist.  The 
World Health Organization (WHO) advises women with a history of venous disease or 
thrombosis, heart disease, stroke, heart attack, liver problems, and migraine headaches avoid 
using OCs.
31  The WHO also recommends that women with breast cancer, heavy smokers aged 
over 35, pregnant women, women taking certain anticonvulsant medications, and women who 
                                                 
28  Women on the Pill Live Longer: Study, Reuters, Mar. 12, 2010,  
http://www.reuters.com/article/idUSTRE62B01R20100312. 
29  Trussell, supra note 2, at 1095. 
30  David A. Grimes, Editorial: Over-the-Counter Oral Contraceptives—An Immodest Proposal?,  
83 AM. J. PUB. HEALTH, 1092 (1993). 
31  Carrie Tatum et. al., Valuable Safeguard or Unnecessary Burden?:  Characterization of 
Physician Consultations for Oral Contraceptive use in Mexico City, 71 CONTRACEPTION 208 
(2005).   9 
will be facing lengthy periods of immobilization avoid OC use.
32  Screening for the WHO’s set 
of contraindications to OC use generally does not require any medical examination.
33  As 
determined by the WHO, physical exams, including a Papanicolaou examination, breast or 
cervical exams, and sexually transmitted infection (STI) screenings are not necessary for women 
to commence using OCs properly and safely.
34   
  Labeling could easily warn women of these risk factors, and potential OC users are 
themselves in by far the best position to know key information such as their ages and whether or 
not they smoke.  The low rates of known or potential contraindications among women seeking to 
obtain OCs for the first time indicates that once again, a simple clear warning on the OC package 
relating to the need to see a physician if one has these conditions or develops certain symptoms 
upon OC use which may be indicative of the existence of these conditions would more than 
suffice to promote user safety.  One 1988 -1989 study of women in Senegal who underwent 
mandatory laboratory testing for cervical cancer, diabetes, high cholesterol, anemia, and liver 
function problems before they received oral contraceptive pills for the first time found that under 
3% of the 410 women who requested the contraceptives had medical contraindications to their 
use.
35  Such a low rate of potential contraindications is an encouraging sign that OTC 
prescription of OCs would not pose serious danger to women’s health.  
  A comparison of the safety of OCs with that of drugs which already enjoy OTC status 
also weighs in favor of making OCs available over-the-counter.  Statistics indicate that aspirin, 
which is widely available OTC and can even be found in vending machines, is more deadly than 
                                                 
32  Id. 
33  Id. at 209 
34  Id. 
35  John Stanback, Safe Provision of Oral Contraceptives:  The Effectiveness of Systematic 
Laboratory Testing in Senegal, 20 INT’L FAM. PLAN. PERSPS. 147 (1994).   10 
OCs.
36  Acetaminophen ingestion results in approximately 56,680 visits to the emergency 
department and 26,256 hospitalizations, as well as 458 deaths, in the United States every year.
37  
Even cigarettes, which end over a thousand lives each day, are much more readily available to 
the public than OCs, which offer so many positive health effects for women.
38 
  Now that the vast majority of OCs prescribed are low-dose products, it is particularly 
unnecessary for a professional to calculate the precise level of OC that is safest for a woman 
before she starts using the drug.
39  The majority of serious medical concerns about OCs in the 
past concerned pills containing 50 micrograms or oestrogen, not newer low-dose models.
40  In 
the 1960s and 70s, higher dose OCs were associated with an increased risk of strokes, heart 
attacks, and the formation of blood clots.
41  Stroke and heart attack risks with low-dose OCs 
seem to be limited to women aged 35 and older who smoke, however, and blood clot formation 
risks are now lower as well.
42  Epidemiological research over the past several decades also 
strongly indicates that the low-dose OCs now in use are safe and effective enough to be marketed 
without prescription to be self-administered by women.
43  Family planning experts no longer 
even recommend that an initial OC product selection be based on choosing an “ideal” product 
because the effects of the most widely prescribed OCs are so similar.
44  It is typical for clinicians 
to prescribe a standard initial product, often the one that is the cheapest or most readily available, 
                                                 
36  Id. 
37  Alastair J.J. Wood et. al., A Sad Day for Science at the FDA, 353 NEW ENG. J. MED. 1197, 
1998 (2005). 
38  Id. 
39  Trussell, supra note 2, at 1096. 
40  Rees, supra note 27, at 41. 
41  Id. 
42  Id. 
43  M. A. Shah, Over-the-Counter Use of Oral Contraceptives in Kuwait, 73 INT’L J. 
GYNECOLOGY & OBSTETRICS 243, 244 (2001) 
44  Trussell, supra note 27, at 1096.   11 
since few women would face health difficulties as a result of using any of the low-dose OCs 
currently on the market.
45   
  If any problems do arise following initial OC use without a prescription, package labeling 
can instruct women to consult a clinician upon the occurrence of certain symptoms.  To support 
adequate safety for OTC OC users, labels should include a clear explanation of OC 
contraindications, instructions for performing breast self-exams and for checking blood pressure, 
and descriptions of danger signs for possible adverse reactions.
46  Labels should also inform OC 
users that they should consult a clinician before using OCs if they have any doubts about whether 
they should be using the drug.
47   
   
IV.  FACTOR TWO IN PRESCRIPTION/OTC ANALYSIS:  EFFICACY AND LOW 
POTENTIAL FOR HARMFUL EFFECTS AS OTC DRUG  
  Reclassifying OCs as OTC drugs would not only be a good idea because of the high 
safety margin of OCs, but also because of the minor potential for OCs made available over-the-
counter to cause harmful effects.  The most immediate concern regarding harmful effects 
resulting from reclassifying OCs as OTC drugs is that doing so might lower the overall efficacy 
of the drugs due to women being less inclined to follow the instructions for their use properly in 
the absence of having to interact with a medical professional in order to obtain the OCs.  In 
response to this concern, it is first important to note that the efficacy of OCs among perfect users 
will not be impacted in any way by a shift from prescription to OTC status and that when used 
perfectly, only about one in a thousand combined estrogen-progestin pill OC users will become 
                                                 
45  Id. 
46  Id. 
47  Id.   12 
pregnant each year.
48  Typical, or imperfect, use results in a significantly higher risk of 
pregnancy; studies vary, however, as to exactly how high this risk is for imperfect users.
49  
Imperfect use includes skipping OC pills and failing to use a backup method of contraception in 
the event that pills are missed, if antibiotics or anticonvulsants are taken, or upon the advent of 
vomiting or severe diarrhea.
50   
  A number of possible causes exist for missed pill imperfect OC use.  These possibilities 
include failing to start a new package of pills in a timely fashion, halting pill use mid-cycle, 
interrupting pill use for one or ore cycles, missing pills by mistake, taking pills significantly later 
than the recommended time, and taking triphasic pills in the wrong order.
51  Current research 
indicates that pissed-pill noncompliance is common even in places where women must currently 
visit clinicians to obtain a prescription for OCs.
52  One of many studies supporting this 
conclusion, which monitored the OC use of 612 women in a United States public health 
department family planning clinic, found that only 42% of these woman always took a pill each 
day, only 17% always took a pill at the same time each day, and only 60% of those who missed 
pills used backup contraception.
53   
  The only real question remaining concerning missed pills, then, is whether such dismal 
rates of optimal OC use would decrease even further if women were not required to obtain a 
prescription to use OCs.  Considering that high patient flow in physicians’ offices frequently 
precludes lengthy discussions regarding OC use and that in the offices of affiliates of the Planned 
Parenthood Federation of America, Inc. most counseling on OC use is currently performed by 






53 Id.   13 
mid-level clinicians and counselors instead of by physicians,
54 any assumption that OC users’ 
compliance levels will suffer in the absence of physician counseling seems at best highly 
speculative. Moreover, discontinuation of OC use has been found to be liked to the occurrence of 
side effects, to pill packaging (with 28-day packs inspiring greater discontinuation than 21-day 
packs), and to pill phasing (with more discontinuation occurring with monophasic than triphasic 
pills).
55  Physicians cannot prevent certain side effects from occurring, alter pill packaging, or 
change pill phasing schedules through consultation alone.  Thus, their input on such matters 
would be of little real value to women who choose to skip or discontinue pill use due to these 
factors. 
  While the majority of pregnancies that occur during a woman’s OC use are probably a 
result of missed-pill noncompliance, there are two other significant factors which reduce the 
efficacy of OCs:  interactions with other drugs, particularly anticonvulsants and antibiotics, 
especially rifampin, and diarrhea or vomiting, including when associated with bulimia or other 
eating disorders.
56  Package labeling already instructs women to use backup contraception under 
these circumstances, but many women do not follow the instructions.
57  It is questionable 
whether women even read, or if they do, comprehend, such instructions; one English study 
showed that half the respondents did not know that OC efficacy could be reduced by 
diarrhea/vomiting or by taking antibiotics.
58 
  Several studies support the conclusion that OC users’ compliance levels will not face a 
precipitous decline in the absence of physician counseling prior to use.  Many of these studies 
                                                 
54  Grimes, supra note 20, at 1093. 
55  Tatum et. al., supra note 31, at 209. 
56  Trussell, supra note 2, at 1097. 
57  Id. 
58   Id.   14 
focus on examining compliance rates in the numerous countries in which OCs are available on 
an OTC basis.  One such study involved trained simulated patients who attended appointments 
with Mexico City public and private physicians in order to request OC prescriptions.  
Immediately upon the completion of each of these appointments, the simulated patients filled out 
a checklist concerning the information provided and examinations performed by the physicians.
59  
The results showed that many physicians failed to ask women questions regarding 
contraindications and to give them instructions for proper OC use.
60  Furthermore, the majority 
of the physicians also failed to discuss the possible side effects of OC use with the patients; only 
in about half of all consultations did the provider explain that the woman might gain weight, and 
other side effects such as headaches, irregular bleeding between periods, and bleary vision were 
discussed at even lower rates.
61  Perhaps most critically, in 71.1% of the consultations, the 
providers neglected to tell the patients that any side effects typically go away after a few 
menstrual cycles.
62  While the Mexico City consultations may well differ significantly from 
United States ones in respect to the information supplied, this study still indicates that trained 
medical professionals who are in possession of all of the key information regarding OC use 
sometimes perform very poorly in actually disseminating this information to patients.  
  Moreover, even assuming that physicians do disseminate all of the key information 
relating to OC use and possible side effects during women’s visits to obtain prescriptions, it is 
highly questionable whether women will actually recall the information so provided well enough 
to act on it.  A 1982 FDA study concluded that a full 40% of patients surveyed could not recall 
their doctor explaining how much medication to take, how to take their medication, or what to do 
                                                 
59  Tatum et. al., supra note 31, at 208. 
60  Tatum et. al., supra note 31, at 211. 
61  Id. 
62  Id.   15 
in the event that they forgot to take it.
63  Due to such natural forgetfulness, it may well be an 
inefficient use of the time of both health care professionals and their patients to keep OCs 
prescription-only based on the faulty assumption that meaningful information which the patients 
will be able to readily recall when they need it is exchanged in these interactions. 
  Another recent study from Kuwait, where OCs are available on an OTC basis, further 
demonstrates that OTC availability does not lead to lower efficacy results due to improper use or 
discontinuation.  A fourth of the Kuwaiti women studied commenced OC use without first 
consulting a doctor, and half bought OCs from a pharmacy.
64  The researchers determined that 
the duration of first-time OC use did not differ based on whether a woman consulted with a 
physician prior to initiating use.
65  Also tellingly, approximately the same percentages of women 
who bought OCs over-the-counter and women who obtained OCs after consulting with a 
physician became pregnant due to imperfect use during the period studied.
66  Based on these 
findings, consultation with a physician does not appear to bolster the proper use of OCs or even 
encourage women to utilize the method for a longer period of time than they would in the 
absence of such advisement.   
  Returning to Mexico, an analysis of a national stratified probability sample of 15,000 
households in which all women aged 15 to 49 were asked to provide detailed histories of their 
contraceptive use for a nearly five-year period, which turned up 4,253 women who used 
contraceptives in that time frame, also found that physician/patient interaction is not a key factor 
                                                 
63  Martha Williams-Deane, Current Oral Contraceptive Use Instructions:  An Analysis of 
Patient Package Inserts, 24 FAM. PLA. PERSPS. 111, 114 (1992). 
64  Shah, supra note 43, at 243. 
65  Id. at 248-49. 
66  Id.   16 
in keeping compliance rates from falling.
67  Women in Mexico were able to obtain their 
contraceptives from a physician, from a family planning clinic, or from a commercial drugstore 
where no questions were generally asked and no safety information was provided.
68  The 
researchers’ actual findings contrasted sharply with their initial hypothesis, which was the users 
obtaining OCs from private physicians or clinics rather than directly from the drugstores would 
have higher continuation rates and lower pregnancy rates due to the information and support 
received from the provider.
69  Women who obtained OCs directly from a drugstore with no 
physician interaction did not in fact have lower rates of continuation of use, and rates of 
pregnancy while using OCs remained similar, at 2-3%, for all three of the source methods.
70  
Interestingly, less educated and illiterate women did not have substantially higher failure rates 
than did the other OC users.
71  
  Some individuals involved in the prescription/OTC debate argue that improved provider-
client communication, not the elimination of provider-client communication, is what is needed to 
improve OC use efficacy rates.
72  Sweden’s switch to OTC distribution of OCs in the mid-1970s, 
which led to a decline in compliance with proper use until the trend was reversed by the passage 
of additional regulations to require the midwives responsible for OC distribution to counsel and 
educate women before giving them the drugs, is cited as an example of the need for greater 
interaction between health care professionals and women receiving OCs.
73  This point, however, 
                                                 
67  Jerald Bailey et. al., Effect of Supply Source on Oral Contraceptive Use in Mexico, 13 STUD. 
FAM. PLAN., 343 (1982). 
68  Id. 
69  Id. 
70  Id. at 345. 
71  Id. at 346. 
72  Amy Allina and Francine M. Coeytaux, Over-the-Counter Distribution of Oral 
Contraceptives, 2 REPROD. HEALTH MATTERS 34, 37 (1994). 
73  Id.   17 
fails to take into account the striking manner in which the Internet has revolutionized access to 
information in recent years.  Today, women with questions about how to use birth control 
properly or about whether certain symptoms were a normal result of OC use can simply either go 
to the website of their OC manufacturer or perform a basic search on google.com for, say, “Do 
oral contraceptives cause headaches?” and quickly find the sought-after information. 
  To provide women with additional information and support regarding OCs without 
continuing to require prescriptions, one idea is to require the installation of computer-based 
displays in locations where OCs are sold which are designed to provide answers to any and all 
OC-related questions.  Computer programs to help women select the absolute best OC choice for 
them based on their personal preferences and capacity to pay could be included, as could a 
variety of videos addressing proper OC use for all brands carried, instructions on what to do in 
the event of improper use, and information on all of the symptoms that users stand a substantial 
risk of encountering.  Women would surely appreciate the convenience and anonymity of 
receiving advice from a nonjudgmental computer screen at the time most convenient to them, 
and since younger, more technologically savvy women make up the majority of Pill users,
74 the 
computer format would feel highly natural to them.
75  
  Studies already show that doctors and patients alike find interactions via Internet 
videoconferencing highly satisfactory.
76  While viewing purely prerecorded materials is not quite 
the same thing as interacting with a live doctor through videoconferencing, this does illustrate 
that direct in-person interaction between patients and physicians is not particularly necessary to 
                                                 
74  Williams-Deane, supra note 62, at 111 (80% of current OC users are under the age of 30). 
75   See Tamar Lewin, If Your Kids Are Awake, They’re Probably Online, N.Y. TIMES, Jan. 20, 
2010, at A1.  
76  See, e.g., Study Finds Virtual Doctor Visits Satisfactory for Both Patients and Clinicians, 
http://www.eurekalert.org/pub_releases/2009-05/mgh-sfv051409.php.   18 
achieve satisfactory information provision.  This is important because compliance with proper 
OC use procedures is linked with the woman’s satisfaction with the clinician, the absence of side 
effects, establishing a daily pill taking routine, and reading the information distributed with the 
OC packaging.
77  The latter three of those elements clearly fall outside the scope of provider-
patient interactions, and if videoconferencing with doctors can lead to patient satisfaction, it 
seems at least possible that interacting with a “clinician” computer program designed to provide 
information could also engender an appropriate degree of patient satisfaction.   
  In a somewhat different vein, it is possible that patient satisfaction with OCs sufficient to 
encourage their continued use can be achieved by giving women greater control over their birth 
control options, which might be accomplished simply by giving OTCs over-the-counter status in 
the first place.  Women choosing to obtain OCs over-the-counter do not have to depend on a 
physician to choose their first contraceptive for them, they are acting on their own behalf, and 
they are somehow arranging to have the cost of the drug covered.
78  A combination of all or 
some of these factors may encourage women to feel more responsible for their behavior, making 
them more inclined to persist in taking OCs and enduring any resulting side effects.
79 
  In order for package labeling to translate into women using OCs properly at high rates, it 
is necessary for such labeling to be complete, to have a user-friendly format, and to achieve a 
high degree of readability.
80  To be complete, OC package insert instructions should tell users 
when to start their first packs of pills, give advice on what to do when pills are missed, and 
discuss the need for back-up contraception use.
81  A national survey of OC users showed a strong 
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preference for the inclusion of longer, more detailed information in package inserts.
82  Women 
particularly favored the inclusion of more information relating to the potential side effects and 
health hazards of OC use.
83  As for formatting, the labeling should be printed in a typeface that is 
appropriately clear, large, and dark.
84  It should also include subject headings that are clearly 
differentiated from the surrounding text so as to make instructions easy to locate.
85  In terms of 
readability, it is essential to keep the average reading level at the fifth-to-sixth grade standard for 
health education materials so that the average woman can comprehend the instructions.
86  
   Lastly, recent case law indicates that even the judicial system is becoming increasingly 
amenable to the view that OCs are appropriate for women to use without first interacting with 
physicians.  Several courts have held that drug manufacturers have a duty to warn consumers 
directly of the dangers associated with OC use.
87  In essence, this means that the courts are 
inclined to view the woman’s role in electing to use OCs as being so important that her 
physician’s role as a “learned intermediary” in prescribing the drug alone is not by itself enough 
to absolve the drug manufacturers of liability.  Through downplaying the physician’s role in OC 
use decisions, the courts are displaying their recognition that the tide is turning toward regarding 
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V.  FACTOR THREE IN PRESCRIPTION/OTC ANALYSIS: METHOD OF USE OR 
COLLATERAL MEASURES NECESSARY TO USE  
  The final factor in making the prescription/OTC determination, namely considering 
method of use and collateral measures pertaining to use, requires an extremely broad analysis.
88 
This analysis includes an inquiry into social policy issues and the circumstances relating to a 
particular drug’s use.
89  On the very broadest level, making OCs available over-the-counter 
would eliminate an important obstacle to their use by combating the incorrect presumption held 
by many women that OC use is dangerous.
90  The very fact of their ready availability would 
signal to women that OCs are in fact quite safe for them to take. 
   Perhaps the most important issue to consider in this regard is the great boon that women, 
and society as a whole, receive as a result of OC use.  Pregnancies, and negative pregnancy-
related health consequences, can disrupt women’s lives and result in substantial societal costs.
91  
The beneficial effects of OCs are becoming increasingly more important as social shifts have 
resulted in the earlier onset of sexual activity by teenagers.  In the 1990s, 50% of teenagers had 
sex by age 18, compared with 27% of members of this age group in the 1950s; by age 20, the 
proportions were 76% and 61%, respectively.
92  In spite of this increase, pregnancy rates among 
sexually experienced teenagers decreased by 19% between 1972 and 1990, indicating that 
increased contraceptive use has played an important role in preventing large numbers of teenage 
pregnancies.   
  As more teenagers engage in earlier sexual activity, it becomes ever more critical for 
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reliable methods of birth control to be easily accessible in order to prevent unwanted 
pregnancies, pregnancy-related complications, and increased numbers of abortions.  One study 
concluded that the likely number of pregnancies averted by adolescent contraceptive use is 
approximately in the 750,000 to 1.25 million range,
93 which would translate into the prevention 
of approximately 480,000 live births, 390,000 abortions, 120,000 miscarriages or stillbirths, and 
10,000 ectopic pregnancies each year.
94  Considering these staggering numbers, making 
contraceptives such as OCs widely available is the cost-effective thing to do.  The average 
annual cost for each adolescent at risk of unintended pregnancy and using no method of 
contraception is estimated to be $5,758 over five years in the private sector and $3,079 in the 
public sector.
95   In contrast, the cost of providing such teenage girls with a contraceptive method 
such as an implant costs approximately $1,533 in the private sector, which represents an 
estimated savings of $4,301.
96   
  One recent report, which compiled research estimating the cost of health care, hosing 
assistance, food stamps, child welfare services, and lost revenue due to lower taxes paid by 
teenage mothers, found that United States taxpayers spent at least $9.1 billion in 2004 for costs 
linked to teenagers having children.
97  If an ounce of prevention is truly worth a pound of cure, 
as the old saying goes, then promoting the availability of OCs to stave off such costs is surely the 
intelligent choice to make. 
  The true cost of teenage pregnancies, however, includes even greater losses to society in 
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terms of lost educational opportunities and future earnings for teenage parents.  Individuals who 
have children during their teenage years are less likely to get a high school diploma or to go on 
to college, they tend to earn less during their time in the workforce, and their unfortunate 
offspring are more likely to struggle to keep up with their peers.
98  Only 40% of teenage girls 
who give birth at age 17 or earlier finish high school, and an even larger gap exists when it 
comes to completion rates for higher education.
99  Consequently, teenage girls who have a baby 
at age 17 or younger earn approximately $28,000 less on average in the 15 years following the 
birth than if they had delayed until just 20 or 21 to have a child, and teenage boys who become 
fathers to children of teenage mothers at age 17 or younger face the loss of a similar amount of 
income over the 18 years following the child’s birth.
100  
   Furthermore, looking to future generations, the daughters of teenage mothers are three 
times more likely to become teenage parents themselves than are girls born to older mothers, and 
the sons born to teenage parents are more likely to be incarcerated.
101  Both sons and daughters 
of teenage parents face an increased risk of both social and academic struggles.
102  Those who 
believe that children thrive best in traditional family units in which both a mother and father are 
present ought to be particularly concerned with the prevention of teenage pregnancy.  Eight out 
of ten teenage fathers do not marry the mothers of their first children, and such absentee fathers 
typically pay less than $800 annually in child support.
103  Thus, on the whole, staving off the 
catastrophic ripple effects created by teenage pregnancies through making OCs more readily 
available to women is, from a social policy perspective, the correct course of action to adopt. 
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  An examination of social issues relating to the prescription/OTC determination for 
regular use OCs must also include a look at the closely related concerns which emerged in the 
relatively recent debate over the prescription/OTC status of emergency OCs.  In 1996, the FDA 
approved the emergency OC pills popularly known as “Plan B” for OTC sale.
104  The FDA’s 
choice to shift Plan B from prescription drug status to nonprescription drug status represented a 
complete about-face from the stance it took against making such a switch just three years 
earlier.
105  In an essay sharing his personal insights into the FDA’s consideration of making the 
change, former FDA consultant Frank Davidoff mentions that during the agency’s consideration 
of Plan B’s manufacturer’s application for approval of OTC marketing of the drug, the 
committees meeting to discuss the issue spent the majority of their time talking about the social, 
behavioral, and ethical issues relating to making the emergency OC so readily available.
106  This 
represented an unusual deviation from the standard practice of FDA committees to discuss 
making a prescription to OTC switch based primarily on the biological and clinical concerns 
raised by the change.
107   
  Five principal social objections to OTC availability of Plan B were raised in the 
committee meetings: 1) requiring prescriptions for emergency contraception is important in that 
it forces women to see doctors on a regular basis, who can provide for their overall health and 
supply them with information; 2) because the mechanism by which Plan B prevents pregnancy is 
not fully understood, implantation of fertilized ova might occasionally be interfered with, which 
some viewed as abortion; 3) increased promiscuity might result from OTC availability, leading 
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to an increase in the spread of STDs; 4) OTC availability might discourage women from using 
other means of contraception; and 5) social and behavioral side effects associated with OTC 
availability might have a greater impact on very young women who might be less capable of 
following instructions for use.
108   
  After much discussion, the committee members voted overwhelmingly (23 to 4) that 
emergency contraception should be available to American women on an OTC basis.
109  Even the 
committee members voting against OTC status acknowledged that they were doing so for 
reasons other than Plan B’s demonstrated safety and efficacy.
110  Although not binding, the FDA 
rarely makes decisions contrary to advisory committee recommendations; in this instance, 
however, the FDA announced its decision that Plan B was not approved for OTC use in May 
2004.
111  As documented by a report of the Government Accountability Office in November 
2005, four unusual occurrences seemingly resulted in this determination.
112  First, the FDA staff 
members who ordinarily would have signed the denial of approval letter so disagreed with the 
decision that they refused to sign it.
113  Second, high-level FDA management was more involved 
in the Plan B review than in reviewing any other OTC switch application.
114  Third, the agency’s 
decision not to approve the application may have been formulated before the scientific reviews 
of the drug were even completed.
115  Finally, the rationale for the decision, namely that younger 
women would be unable to use Plan B appropriately, failed to follow the FDA’s usual practice of 
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extrapolating data from older to younger adolescents.
116 
  Strong suspicions existed that pressure from social conservatives led to the FDA’s initial 
refusal to approve Plan B for OTC status.  Indeed, W. David Hager, an obstetrician-gynecologist 
recruited directly by the second President Bush’s White House to serve on the committees 
discussing Plan B approval, even said of the Plan B decision in one speech to a Christian college 
audience that “God has used me to stand in the breach for the cause of the Kingdom.”
117  Such 
statements by a White House recruitee suggest that pressure was placed on the FDA from the 
highest levels of the executive branch to reject Plan B’s OTC approval. 
  The same social concerns which the FDA advisory committees discussed in relation to 
Plan B are extremely likely to crop up again in talks regarding shifting regular use OCs to over-
the-counter status.  Particularly if a Republican administration is in place at the time of the 
decision, a strong possibility also exists for social conservatives to allow their desire to impose 
their set of beliefs on women across the United States to cloud a fair assessment of the proper 
status of OCs.  It is to be hoped that future FDA decisions on the prescription/OTC status of OCs 
will place stronger emphasis on their safety and efficacy instead of allowing social views with 
dubious measures of objective support to cloud the agency’s judgment. 
  One more social policy argument that is sometimes brought up in support of keeping OCs 
prescription-only is that “birth control is a poor woman’s ticket to health care,” since a visit to a 
family planning clinic “is her annual exam, when she gets a Pap smear, blood pressure check, 
and general health information.”
118  This argument relies on the faulty presumption that in order 
to lure women in to have regular health examinations, the presence of an accompanying “carrot” 
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in the form of a prescription for OCs is necessary.
119  It should be noted that men face no 
comparable coercion to undergo regular health screenings, yet no one seems to be suggesting 
that items such as male condoms ought to require prescriptions simply in order to induce men to 
come in for check-ups.
120  This argument is highly paternalistic in that it suggests that 
policymakers should be the ones who decide essentially to force women into seeing doctors on a 
regular basis to obtain OC prescriptions instead of allowing women to make decisions regarding 
doctor’s visits for themselves. 
121  
  A related line of concern is that that giving OCs over-the-counter status could jeopardize 
the very survival of family planning clinics.  This is because financial support for such clinics is 
to a substantial degree based on reimbursement associated from contraceptive distribution, 
particularly OCs.
122  The weight of this line of reasoning may be diminished by national health 
care reform measures which may alter the reimbursement system for family planning.
123   
  The manner in which insurance coverage of OCs might change upon their switch to OTC 
availability is another issue worthy of examination.  Concerns have been raised that insurance 
policies which cover prescription drugs might no longer pay for OCs should they become 
available over-the-counter.
124  Moreover, some argue that OC manufacturers might stop offering 
steep price discounts to family planning clinics due to the move to OTC status, which might 
result in poor women who are currently able to gain access to OCs inexpensively being forced to 
pay higher, potentially unaffordable prices.
125  Others counter this point by arguing that 
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manufacturers would have a strong incentive to continue such discounts in an effort to create 
brand loyalty should OC distribution be increased through nonprescription approval of the 
drugs.
126  Whatever the shift in cost allocation for OCs upon their OTC availability, however, 
making OCs accessible without a prescription would almost certainly decrease the overall social 
cost of their use through eliminating the administrative costs associated with prescriptions and 
the costs associated with visiting a clinician to obtain OCs.
127 
  A final social concern relating to the OTC availability of OCs is that since OCs, unlike 
barrier methods, offer no protection from STDs, some individuals may choose to use only OCs 
for their contraceptive needs if the drugs become more available, thereby placing themselves at 
greater risk for contracting STDs.  This concern does not, however, justify keeping OCs as 
prescription-only drugs.  Sexually active individuals are at risk for STDs whether they use 
hormonal contraceptives, the withdrawal method, intrauterine devices, male and/or female 
sterilization, and, with respect to at least HIV infection, possibly also spermicides.
128  The proper 
public health response to counter the spread of STDs is increased education on recognizing and 
reducing the risk of contraction, not restricting of one or more methods of contraception.
129  One 
promising possibility for accomplishing this is for condoms and information on assessing STD 
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VI.  OCs SHOULD REMAIN OTC DRUGS RATHER THAN BECOME BTC (BEHIND-
THE-COUNTER) DRUGS 
  Once the FDA decides to abandon the current physician’s prescription-only system for 
OCs, a further question of whether OCs should become available over-the-counter or whether 
they belong in some new behind-the-counter distinction.  While no such category currently 
exists, there has been discussion in recent years about possibly establishing a BTC category.  In 
the event that a BTC category is established, OCs ought to remain in the OTC category, albeit 
possibly in a “restricted-sale” segment of the OTC category along with Plan B, instead of 
becoming BTC drugs in order to keep OC prices down, promote access to the drugs, and 
minimize the risk of pharmacist interference with women’s OC use decisions. 
  In the FDA’s notice of its upcoming November 14, 2007 public meeting to assess the 
need for this new classification of drugs, the agency defined the BTC class of drugs as 
“comprised of certain medications available behind the counter at the pharmacy without a 
prescription and require[ing] the intervention of a pharmacist before dispensing.”
131  BTC drugs 
could take three possible forms: a separate third class of drugs that is neither nonprescription nor 
prescription, prescription drugs, or nonprescription drugs.
132  Prescription BTC drugs would 
require a prescription by the pharmacist rather than by a physician, whereas nonprescription 
BTCs would require pharmacist intervention without the issuance of an actual prescription 
before purchase of the drug.
133 Due to the current two-category system provided for by the 
FD&C Act, some argue that the FDA lacks the statutory authority to choose the first of these 
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options and create a separate, discrete BTC drug class.
134  Regardless of whether this argument is 
correct, Congress could still elect to provide for the creation of such a category through 
legislation if it so chose.
135   
  For clarity’s sake, it is important to note that while certain OTC medications are already 
thought of as being “behind the counter,” namely Plan B and drugs containing pseudoephedrine, 
these drugs are not in a formal BTC category and their current treatment is different from that 
which would occur if they were officially made BTC drugs.
136  Plan B and pseudophedrine are 
only kept physically behind the pharmacy counter in order for age and quantity restrictions to be 
enforced.
137  These drugs do not require, as the proposed BTC class would, pharmacist 
counseling, consultation, or interaction and are frequently dispensed by members of the store’s 
staff without any interaction between pharmacist and purchaser whatsoever.
138  In fact, should a 
true BTC class be created, it would be a good idea for Plan B and pseudophedrine to be referred 
to as something along the lines of “restricted-sale” drugs to keep public, pharmacy, and 
insurance confusion to a minimum.
139   
  While it might in fact be a good idea for OCs to join these “restricted-sale” drugs in being 
physically placed behind pharmacist counters once they become available OTC in order to 
ensure that they will not be tampered with before their use, there is no need to require purchasers 
to interact directly with pharmacists before receiving OCs as would be the case with true BTC 
drugs.  First and foremost, aside from the issue of whether OCs belong in a BTC class if BTC 
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classes were in fact shown to be effective, the need for any kind of BTC class whatsoever 
remains unclear.  A 1995 report by the Government Accountability Office (GAO) entitled 
“Value of Pharmacist-Controlled Class Has Yet to Be Demonstrated” examined variations on 
BTC classes already in existence in ten other nations.
140  The report reached the conclusion that 
there is insufficient data to link the creation of a BTC class of drugs to improved health incomes, 
lower cost, or expanded access.
141  Additionally, the report found that while pharmacy 
counseling was mandated as a part of the BTC categorization plan in these other nations, it rarely 
occurred in practice.
142  Considering these unpromising findings, the formation of any kind of 
BTC category, much less one including non-emergency OCs, seems unnecessary. 
  In some countries, including Canada as of 2008, Plan B is now available directly off the 
shelf as opposed to being kept behind the pharmacy counter.
143  This change eliminated privacy 
concerns created by requiring women to receive counseling from a pharmacist prior to receiving 
the drug, most notably that many pharmacies lack private consulting rooms and, in some areas, 
pharmacists recorded this very private information and stored it in patient files.
144  It was also 
estimated that the elimination of the consulting requirement might ultimately work to lower the 
cost of the drug, since the drug’s cost included dispensing and counseling fees added on by the 
pharmacies themselves to cover the additional services.
145  Since cost is certainly barrier to 
access, especially for younger women, and research suggests that these privacy issues constituted 
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an additional access barrier,
146 not placing OCs in a BTC category in the United States might 
well better serve women and society in general by increasing access to and use of OCs. 
  In addition to alleviating privacy and cost concerns, keeping OCs over-the-counter with, 
possibly, a “restricted sale” distinction but not making them BTC has the added benefit of 
limiting pharmacists’ ability to interfere, based on religious or other beliefs, with women’s 
decisions about their own bodies.  Pharmacist refusals to fill prescriptions for birth control based 
on their personal beliefs are being increasingly reported around the world, including in the 
United States.
147  Pharmacists who refuse to dispense birth control also often refuse to transfer a 
woman’s prescription to a different pharmacist or refer her to another pharmacy so that she can 
obtain the medication.
148  Perhaps most disturbingly of all, some pharmacists have been known 
to confiscate prescriptions, mislead women about the availability of drugs, subject women to 
lectures on what, in the pharmacist’s view, constitutes morality, and/or to delay women’s access 
to the requested birth control drugs until the critical period for effective administration has 
passed.
149  Especially if a prescription BTC class is introduced in which women are required to 
obtain a pharmacist’s prescription rather than a doctor’s prescription in order to obtain OCs, 
pharmacist meddling poses a serious risk to women’s access to the drugs which allow them to 
control their reproductive destinies.  Making OCs available over-the-counter instead of moving 
them to some variety of BTC classification is the best option for minimizing the risk of 
pharmacists interfering with women’s birth control decisions. 
  Even if OCs were classified as BTC drugs, both pharmacists’ ability to assess women’s 
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risk for contraindications and the quality of the information passed along to the women by 
pharmacists would be questionable.  In a study of OC provision in Jamaica, where low-dose OCs 
have been classified as BTC drugs to be dispensed only by pharmacists and requiring counseling 
about proper use since 2008,
150 a substantial number of mystery clients posing as new pill users 
were denied access to OCs even though they had no contraindications.
151  Also troubling was the 
relevance of the information that the pharmacists passed along to the mystery clients, particularly 
regarding side effects of OC use.  While the majority of pharmacists were knowledgeable about 
all aspects of pill use, as their responses to survey questions indicated,
152 pharmacists tended to 
focus only on one side effect of use—namely, weight gain—which has actually been shown to be 
incorrectly attributed to OC use.
153  Costly, user-deterring consultations which offer a significant 
opportunity for pharmacists to interfere with patients’ own birth control-related convictions 
simply do not seem to provide enough pros to outweigh the cons when it seems that the 
interactions may well prove so very unhelpful. 
 
VII.  CONCLUSION 
 In light of the FDA’s mission, which is supposed to involve prioritizing above all else 
the promotion of the public health through “promptly and efficiently reviewing clinical research 
and taking appropriate action on the marketing of regulated products in a timely manner,”
154 the 
FDA has failed the citizens of the United States in the area of the drug status classification of 
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oral contraception.  The public’s health will be best promoted through increasing women’s 
access to OCs, and this access should remain OTC instead of BTC in order to achieve optimal 
results in terms of promoting access, reining in costs, protecting privacy, and preventing 
pharmacist interference with women’s reproductive choices. 